Stereotaxis (STXS) closed at $1.03 on November 10, 2026, down 9.6% from the previous close, on volume of 712,208 shares (30-day average 675,836).
Data as of November 10, 2026.
10-Nov-2026
Stereotaxis Reports Third-Quarter Revenue Growth Amid Operating Loss
TipRanks (Tue, 10-Nov 4:47 PM ET)
Stereotaxis launches convertible notes offering of up to $24M
Seeking Alpha News (Tue, 10-Nov 4:14 PM ET)
Stereotaxis GAAP EPS of -$0.07 misses by $0.02, revenue of $8.9M misses by $0.7M
Seeking Alpha News (Tue, 10-Nov 4:04 PM ET)
Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates
Globe Newswire (Tue, 10-Nov 4:02 PM ET)
Stereotaxis Announces Convertible Note Financing of Up To $24 Million
Globe Newswire (Tue, 10-Nov 4:01 PM ET)
Here are the major earnings after the close Tuesday
Seeking Alpha News (Tue, 10-Nov 10:00 AM ET)
Stereotaxis Q3 2026 Earnings Preview
Seeking Alpha News (Mon, 9-Nov 5:35 PM ET)
Globe Newswire (Mon, 2-Nov 8:48 AM ET)
Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
Globe Newswire (Fri, 30-Oct 8:03 AM ET)
Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia
Globe Newswire (Thu, 22-Oct 8:04 AM ET)
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Stereotaxis trades on the AMEX stock market under the symbol STXS.
As of November 10, 2026, STXS stock price declined to $1.03 with 712,208 million shares trading.
STXS has a beta of 1.47, meaning it tends to be more sensitive to market movements. STXS has a correlation of 0.10 to the broad based SPY ETF.
STXS has a market cap of $103.21 million. This is considered a Micro Cap stock.
Last quarter Stereotaxis reported $8 million in Revenue and -$.05 earnings per share. This fell short of revenue expectation by $-910,000 and missed earnings estimates by -$.01.
In the last 3 years, STXS traded as high as $3.59 and as low as $.80.
The top ETF exchange traded funds that STXS belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
STXS has underperformed the market in the last year with a return of -62.1%, while the SPY ETF gained +12.9%. In the last 3 month period, STXS fell short of the market, returning -27.5%, while SPY returned -2.8%. However, in the most recent 2 weeks STXS has outperformed the stock market by returning +4.0%, while SPY returned -2.0%.
STXS support price is $1.08 and resistance is $1.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STXS shares will trade within this expected range on the day.